

Research Article

Predicting Mortality Rate in ICU-Admitted COVID-19 Patients Implementing Visual Semi-Quantitative CT Severity Scoring System

Azadbakht J^{1*}, Lajevardi ZS² and Abdoli AH²¹Department of Radiology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran²Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran***Corresponding author:** Javid Azadbakht,

Department of Radiology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran

Received: November 01, 2021; **Accepted:** November 26, 2021; **Published:** December 03, 2021**Abstract**

Objectives: The aim of this study was to identify the clinical and laboratory features and CT scan (CT intensity score and pleural effusion) associated with COVID-19 pneumonia to evaluate the relationship between CT scan findings and mortality by comparing deceased patients with normal patients.

Methods: In this retrospective case-control study, 290 ICU admitted patients with RT-PCR confirmed COVID-19 pneumonia were investigated. Totally, 150 deceased patients (with confirmed COVID-19 related death) were extracted from the COVID-19 registry of the affiliated university hospital belonging to mentioned period of time (in-hospital mortality subgroup, case), and 150 patients who survived the admission course were randomly selected from the same data set (surviving subgroup, control). Available electronic records for each patient were enlisted, including laboratory and clinical information, and their on-admission Computed Tomography (CT) images were reviewed. Mortality-related risk factors were compared between case and control subgroups.

Results: The mean age of deceased patients (68.20 ± 16.07) was significantly higher than that of the surviving patients (54.72 ± 19.50) ($p < 0.001$). Diabetes, hypertension, and Chronic Kidney Disease (CKD) were significantly related with higher mortality rates (62.2%, 58.7%, and 80.4% mortality in diabetic, hypertensive, and CKD patients versus 41.7%, 42.1%, and 35.9% in non-diabetics, normotensives, and patients without CKD). Additionally, the mean on-admission air-room SPO₂ level in deceased patients (90%) was significantly lower than that of the survivors (93%) ($p = 0.001$). Lymphocyte count, Neutrophil to Lymphocyte Ratio (NLR), Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP), Lactate Dehydrogenase (LDH), fasting Blood Sugar (BS), Blood Urea Nitrogen (BUN), and Creatinine (Cr), mean CT severity score (CT-ss), and O₂ supportive therapy requirement were significantly higher in the mortality subgroup ($p < 0.05$). Pleural effusion showed no significant correlation with short-term mortality. CT-ss of >11 , in isolation or in combination with above-mentioned prognosticators, was 64% or 81.4% sensitive, and 60% or of 78.6% specific, to predict mortality.

Conclusions: Factors such as advanced age, underlying diseases such as diabetes, hypertension, and CKD, decreased air-room SPO₂, and increased lymphocyte count, higher NLR, ESR, CRP, LDH, BS, BUN, and Cr level, as well as higher CT-ss and O₂ supportive therapy, are all significantly correlated with higher mortality in ICU-admitted COVID-19 patients.

Keywords: COVID-19; CT scan; CT severity score; ICU; Pneumonia

Introduction

In Dec 2019, a series of pneumonia cases linked to a seafood and wet animal wholesale market emerged in Wuhan, Hubei, China [1]. Deep sequencing analysis from lower respiratory tract samples indicated a novel coronavirus, which was named 2019 novel coronavirus (2019-nCoV) [2], which after about 20 whole months yet represents a major threat to global health. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new virus responsible for multiple outbreaks of respiratory illness known as COVID-19 throughout the world, has sickened more than 240 million people

and killed nearly 5 million patients as of 22 Oct, 2021 [3]. The clinical spectrum of COVID-19 pneumonia ranges from mild to critical cases, among which the diagnoses of ordinary, severe, and critical cases were all correlated with chest Computed Tomography (CT) findings [4,5]. WHO had declared that this situation should be deemed a public health emergency of international concern on 30 Jan 2020 [6]. Major clinical and paraclinical features of patients with 2019-nCoV Induced Pneumonia (NCIP) include fever and/or respiratory illness, lymphopenia, and radiologic abnormality [6-8]. Computed Tomography (CT) is capable of accurately assessing the condition of the lungs' parenchyma and is available in many medical centers

worldwide [9]. Chest CT scan is relatively sensitive for detecting the initial evidence of COVID-19 pneumonia, which crucially helps to increase the effectiveness of early-onset therapy. In asymptomatic or mildly symptomatic COVID-19 patients in the early stages of the disease, CT scan plays a vital role in timely diagnosis [5]. Moreover, CT may help to predict the final prognosis early in the disease course.

Herewith, we investigated 290 ICU-admitted RT-PCR confirmed COVID-19 patients into two 150 mortality and surviving subgroups, describing the clinical, laboratory, and radiological characteristics and comparing the results between these two subgroups.

Methods and Materials

This study was approved under a waiver of informed consent by the Institutional Review Board (IRB).

Study population

This retrospective study was performed between 20 Aug, 2021 and 21 Sep, 2021 in a tertiary teaching center in an early epicenter of COVID-19. Medical records of 290 eligible ICU-admitted RT-PCR confirmed COVID-19 patients who underwent chest CT scan on admission date were extracted. In general, 145 patients deceased in admission course (case); to design a case-control analysis and increase the study power, we used a 1:1 ratio of control, investigating 150 surviving patients discharged after significant clinical recovery (control). Patients with an underlying pulmonary disease, potentially capable of confounding CT images interpretation (pulmonary fibrosis and emphysema), and patients with positive blood culture for other infectious agents, causative of pneumonia, and patients with chest CT images taken with technical errors (artifacts) were excluded from the study.

Clinical and laboratory findings

Duration of hospitalization, presence of COVID-19 related symptoms, the time interval between symptom onset and admission date (same as the time interval between symptom onset and initial chest CT), on-admission respiratory rate and air-room SPO₂, need for O₂ supportive therapy (through nasal cannula or mechanical ventilation) were noted. In addition, the presence of underlying diseases such as DM, HTN, heart disease, chronic kidney and liver disease, and malignancies were recorded. WBC (white blood cell) count, neutrophil count, lymphocyte count, NLR, ESR, CRP, LDH, Creatinine Phosphokinase (CPK), Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), troponin, BUN, Cr, BS, and history of long-term (at least for three months) glucocorticoids administration were also enlisted.

Image acquisition

All CT scans were performed using a multi-slice scanner (Alexion TSX-034A, Toshiba, Japan) at maximum inspiration affordable by patients, hands up and in the supine position, without prescribing intravenous contrast material. CT parameters were set as per the local institutional low-dose CT protocol: Pipe voltage: 120kVp; tube current: 100 mA with automatic exposure control, slice thickness: 3 mm, step coefficient: 1. The mean CTDIvol was 5.1mGy (range: 3.8-7.8mGy). Low-dose CT has been found to substantially decrease the radiation exposure in both CT department staff and patient without compromising NCIP detection in CT [10].

Image interpretation

Two radiologists examined chest CT images independently, obviating mismatches with a consensus approach. All included chest CTs were randomly encoded and anonymously identified by colleagues who were not involved in this investigation to blind contributing authors to the final result. All CT images were viewed in lung window settings (WW, 1600 HU; WL, -500 HU) to calculate semi quantitative CT severity score and mediastinal window setting (WW, 400 HU; WL, 40 HU) to evaluate the presence of pleural effusion.

Affected pulmonary lobes were recorded (upper right lobe, right middle lobe, right lower lobe, upper left lobe, and lower left lobe). A semiquantitative CT severity scoring (CT-ss) system has been used to visually estimate the extension of pulmonary involvement in each lobe and assign a score to every lobe (ranging between 0-5), and then adding up five different lobe scores to give the overall CT-ss (ranging between 0-25), as implemented in previous studies (11, 12): score 0, no lobar involvement; score 1, 1% - 5% lobar involvement; score 2, 6% - 25% lobar involvement; score 3, 26% - 50% lobar involvement; score 4, 51% - 75% lobar involvement; and score 5, 76% - 100% lobar involvement. The presence and severity of pleural effusion (minimal, mild, moderate, severe) were also recorded.

Statistical analysis

Data were first collected and entered into SPSS software version 22, using descriptive statistics (frequency distribution and central indices and dispersion) and inferential statistics (t-test to compare the mean of quantitative variables between survived and deceased patients, and Chi-square test to analyze the relationship between categorical variables and patient mortality). Significant predictors were then identified using the univariate model. In the next step, the multivariate conditional logistic regression model was used to design a model indicating the relationship between considered variables and patients mortality rate. Only variables with a p-value of less than 0.25 were included in the model. The results of the Omnibus test are acceptable model fit and significant at an error level of less than 0.001. After determining the significant predictor(s), the sensitivity and specificity (accuracy) of predicting mortality was measured for the CT-ss alone and with other model predictors through analyzing ROC curves.

Results

In this study, medical records/chest CT images of 290 RT-PCR confirmed ICU admitted COVID-19 patients (145 surviving admission course and 145 deceased in hospital) were reviewed and enlisted.

The results in Table 1 show that deceased patients' mean age (68.20 16 16.07) was significantly higher than that of surviving patients (54.72 19 19.50) ($p < 0.001$). Also, the presence of diabetes, hypertension, and CKD was significantly correlated with a higher mortality rate in COVID-19 patients (62.2% mortality rate in diabetic patients versus 41.7% in non-diabetics, 58.7% mortality rate in hypertensive patients versus 42.1% in normotensive patients, and 80.4% mortality rate in patients with CKD versus 35.9% in patients without CKD). The presence of symptoms before admission was significantly associated with higher mortality rates, as 52.1% of




Figure 1: ROC curves for CT-ss alone (red) and with other model predictors (blue) to predict mortality rate in COVID-19 patients.

patients who were symptomatic pre-admission died in hospital, while the mortality rate in patients who were symptom-free before admission was only 28% ($p = 0.036$). The mean air-room SPO_2 level on the first day of admission in deceased patients (90%) was significantly lower than that of survived subgroup (93%) ($p = 0.001$) (Figure 1). The mean value of lymphocyte count, NLR, ESR, CRP, LDH, BS, BUN, and Cr in the deceased subgroup were significantly higher than those of survived subgroup ($p < 0.05$). Moreover, the mean CT-ss in deceased patients was significantly higher than that of survived patients ($p < 0.001$). Finally, the need for respiratory supportive therapy (O₂ therapy via nasal cannula and mechanical ventilation) was meaningfully associated with a higher mortality rate (52.1% mortality in patients undergoing O₂ therapy versus 32.3% in patients not receiving O₂ therapy; and 78% mortality in patients requiring mechanical ventilation versus 33.1% in patients who did not undergo mechanical ventilation).

A logistic regression model was implemented to model the relationship between the aforementioned variables and in-hospital mortality rate, the results of which are presented in Table 2. It should be noted that only variables with p-values of less than 0.25 were incorporated into the multiple logistic regression model (namely gender, age, DM, HTN, CKD, Liver disease, symptom to admission time interval, dyspnea, respiratory rate, SPO_2 , lymphocyte count, NLR, ESR, CRP, LDH, CPK, AST, ALT, BS, BUN, Cr, CT-ss, receiving nasal O₂ therapy, undergoing mechanical ventilation, long-term glucocorticoid therapy).

In Table 2, only significant variables (with a p-value of < 0.05) are tabulated.

According to Omnibus test results, the model fit is acceptable, and at an error level of less than 0.001, the model is significant. Additionally, the value of the coefficient of determination (Pseudo R-square) shows that 26 variables considered were able to explain alterations in patient mortality rate in 40.8 to 54.4% of the case. Moreover, according to the values of parent statistics and p-values,

it can be concluded that among the 26 variables considered, only 5 variables (age, CKD, CT-ss, ventilation, and long-term glucocorticoid therapy) have a significant relationship with the mortality rate in COVID-19 patients. According to OR values, one year of increase in age increases the chance of death by 1.041 times, and an increase in the CT-ss by one unit increases the chance of death by 1.099 times. Mortality rate in CKD patients is 4.3 times higher than that of patients without CKD, and in patients who required ventilation is 10.4 times of that of patients who did not require ventilation. Lastly, the mortality rate among patients who are not under corticosteroid therapy is 3.08 times ($1 \div 0.324$) of that of patients who receive corticosteroids.

Eventually, the ROC curves (Table 3) were plotted to test the predictive value of the CT-ss as a single factor and to define a properly discriminating cut-off value.

The results of Table 3 show that CT-ss alone can predict mortality with a cut-off point of 12.5 with an average power (area under the curve (AUC) of 0.653); however, when combined with other model predictors, predictive power increases by nearly 20% (0.852).

Discussion

Our study showed that the semiquantitative CT-ss, as a reflector of extension of lung parenchyma involvement, could meaningfully predict mortality rate in patients with COVID-19 pneumonia. Adding up patients age and other clinical factors (those affecting patients mortality according to our results), such as CKD, need for undergoing mechanical ventilation, and long-term glucocorticoids administration, can increase the predictive power of the model by up to 20% (area under the curve of 0.852) and can help to distinguish COVID-19 patients with different clinical stages to quickly mark out critical cases and look them out intensely, as an attempt to wisely allocate resources thus reducing mortality.

In a retrospective study by Mingli Yuan et al., the mean age, underlying comorbidities, and mean CT-ss (30 versus 12 in survived patients) in the mortality group were meaningfully higher than

Table 1: Demographic, clinical, laboratory, and imaging findings and final clinical outcome in studied patients.

		Variable	Total	Survived patients	Deceased patients	p-value	
Demographic	Gender	Male	135 (46.6)	74 (54.8)	61 (45.2)	0.158	
		Female	155 (53.4)	71 (45.8)	84 (54.2)		
		Age	61.46 ± 19.08 (3-99)	54.72 ± 19.50	68.20±16.07	0	
Comorbidities	DM	Yes	115 (39.7)	43 (37.4)	72 (62.6)	0.001	
		No	175 (60.3)	102 (58.3)	73 (41.7)		
	Hypertension	Yes	138 (47.6)	57 (41.3)	81 (58.7)	0.007	
		No	152 (52.4)	88 (57.9)	64 (42.1)		
	Heart disease	Yes	98 (33.8)	51 (52.0)	47 (48.0)	0.71	
		No	192 (66.2)	94 (49.0)	98 (51.0)		
	CKD	Yes	Acute	57 (62.0)	18 (19.6)	74 (80.4)	0
			Chronic	35 (38.0)	127 (64.1)	71 (35.9)	
			No	198 (68.3)			
	Chronic liver disease	Yes	Acute	12 (85.7)	4 (28.6)	10 (71.4)	0.171
			Chronic	2 (14.3)	141 (51.1)	135 (48.9)	
			No	276 (95.2)			
Cancer	Yes	Brain	1 (10.0)	3 (30.0)	7 (70.0)	0.334	
		Gastrointestinal	2 (20.0)	142 (50.7)	138 (49.3)		
		Blood & Lymphatic tissue	6 (60.0)				
		Urinary	1 (10.0)				
		No	280 (96.6)				
Clinical	Symptom to admission	Yes	265 (91.4)	127 (47.9)	138 (52.1)	0.036	
		No	25 (8.6)	18 (72.0)	7 (28.0)		
			Symptom to admission interval (day)	5 (2-7)	5 (2-7)	4 (2-7)	0.805
	Dyspnea	Yes	202 (69.7)	93 (46.0)	109 (54.0)	0.055	
		No	88 (30.3)	52 (59.1)	36 (40.9)		
			RR (per minute)	20.84±7.93	20.06±7.71	21.62±8.09	0.093
		SPO ₂ (%)	91 (86-95)	93 (87.5-96)	90 (85-93)	0.001	
Laboratory			WBC (*10 ⁹ /L)	6.7 (4.65-10.5)	6.7 (4.75-10.75)	6.7 (4.5-10.35)	0.99
			Neutrophil count (*10 ⁹ /L)	5 (3-8)	4.91 (3-7.58)	5 (3-8.09)	0.288
			Lymphocyte count (*10 ⁹ /L)	1 (1-1.91)	1 (1-2)	1 (1-1.29)	0.001
			NLR	4 (2.44-7)	3.5 (2-5.96)	4.5 (3-7.61)	0.004
			ESR (mm)	26 (11-39.25)	16 (8.5-32)	35 (13-51.5)	0
			CRP (mg/L)	46 (18-63)	32 (10-61.5)	54 (30-63.5)	0.001
			LDH (IU/L)	646 (489-874.25)	579 (474.5-823.5)	713 (542-952)	0.002
			CPK (IU/L)	125.5 (69-267.25)	112 (59-221)	143 (77-296.5)	0.105
			AST (IU/L)	38 (25-59)	35 (25-57)	39 (26-59.5)	0.112
			ALT (IU/L)	23 (18-41)	26 (19-45)	22 (17-36.5)	0.131
			Troponin (ng/L)	4 (3-5)	4 (3-5)	4 (3-5)	0.43
			BS (mg/dL)	128.5 (102-193.25)	121 (100.5-181)	135 (106-212)	0.03
			BUN (mg/dL)	19 (13-30)	16 (12-25)	24 (16-34)	0
			Cr (mg/dL)	1.1 (1-1.42)	1 (0.9-1.3)	1.2 (1-1.6)	0

		Semi-quantitative CT-ss		12.34±4.86 (2-23)	11.09±4.71	13.59±4.70	0	
Imaging	Pleural effusion	Yes	Minimal	41 (14.1)	49 (53.3)	43 (46.7)	0.449	
			Mild	34 (11.7)	96 (48.5)	102 (51.5)		
			Moderate	15 (5.2)				
			Severe	2 (0.7)				
	No			198 (68.3)				
	Intubation			Yes	4 (1.4)	4 (100)	0	0.122
		No	286 (98.6)	141 (49.3)	145 (50.7)			
Ventilation			Yes	109 (37.6)	24 (22.0)	85 (78.0)	0	
			No	181 (62.4)	121 (66.9)	60 (33.1)		
Outcome	O ₂ therapy			Yes	259 (89.3)	124 (47.9)	135 (52.1)	0.037
				No	31 (10.7)	21 (67.7)	10 (32.3)	
	Chronic GC use			Yes	85 (29.3)	47 (55.3)	38 (44.7)	0.246
				No	205 (70.7)	98 (47.8)	107 (52.2)	
Hospital length of stay (day)				9 (5.75-15)	9 (6-14)	10 (5-16)	0.772	

ALT: Alanine Transaminase; AST: Aspartate Aminotransferase; BS: Fasting Blood Sugar; BUN: Blood Urea Nitrogen; CKD: Chronic Kidney Disease; CPK: Creatinine Phosphokinase; Cr: Creatinine; CRP: C-Reactive Protein; CT-ss: CT Severity Score; DM: Diabetes Mellitus; ESR: Erythrocyte Sedimentation Rate; GC: Glucocorticoid; LDH: Lactate Dehydrogenase; NLR: Neutrophil to Lymphocyte Ratio; RR: Respiratory Rate; WBC: White Blood Cell.

Table 2: Factors affecting patient mortality based on logistic regression model.

Variable	B	SE	Wald	p-value	OR (95% CI)
Age	0.041	0.011	13.762	0	1.041 (1.019-1.064)
CKD	1.466	0.44	11.086	0.001	4.332 (1.828-10.270)
CT-ss	0.094	0.04	5.478	0.019	1.099 (1.015-1.189)
Ventilation	2.345	0.407	33.251	0	10.430 (4.701-23.142)
Chronic GC use	-1.128	0.408	7.663	0.006	0.324 (0.146-0.719)

Model information: Omnibus test = 151.866, p < 0.001.

Pseudo R-square = (0.408, 0.544).

CKD: Chronic Kidney Disease; CT-ss: CT Severity Score; GC: Glucocorticoid.

Table 3: CT-ss as a single mortality predictor.

	Cut-off	Sensitivity	Specificity	AUC (95% CI)	p-value
CT-ss	12.5	64.80%	60%	65.3% (59-71.6)	0
Model	-	81.40%	78.60%	85.2% (80.8-89.6)	0

CT-ss: CT Severity Score.

those of the survival group. In their study, there was no significant relationship between pleural effusion and mortality, which is in keeping with our results. Their study showed that a simple CT scan scoring method is capable of predicting mortality with sensitivity of 85.6% and specificity of 84.5% [13]. In a study conducted by Kunhua Li et al., severely ill patients were older, had underlying comorbidities more frequently, and reported shortness of breath more commonly compared to patients with milder infection. Lymph node enlargement, pericardial effusion, and pleural effusion were more commonly seen in severely ill patients, and CT-ss of severe/critical patients were significantly higher than that of patients with a milder course disease (mean CT-ss of 11 vs. 5) [14]. In an investigation by Peijie Lyu et al., critical cases had a higher overall CT-ss compared to mild/severe cases (CT-ss of 9 to 17 vs. 2 to 14), and pleural effusion was more commonly and more severely seen in the former group (33% versus 13%). CT-ss with a sensitivity of 67% and a specificity of 74% can help to diagnose the severity of the disease [15]. In a study by Kazemi et al., elderly patients, cases with shortness of breath, the presence

of comorbidities, especially cardiovascular conditions, and pleural effusion were significantly associated with poorer prognosis. There was a strong correlation between CT-ss and final clinical outcome, and CT-ss of 11.5 was suggested as a reasonable cut-off with 67.4% sensitivity and 68.7% specificity in differentiating patients with poor prognosis (patients who needed ICU hospitalization or died). According to literature, CT-ss and chest CT features and, most importantly, pleural effusion can serve as dependable prognosticators in COVID-19 patients [16]. In another research, multivariate regression analysis showed a significant increase in in-hospital death rate for patients with higher CT intensity scores on admission, with no meaningful reported mortality rate difference between patients with and without pleural effusion discernible in chest CT imaging. The results from this study indicated that mortality rate remain significantly higher in patients with higher CT intensity scores even after adjustment for clinical, demographic, and laboratory parameters [17].

These findings indicate the need to determine a single, clear, and enforceable scoring system. A CT-ss can accurately mark out hospitalized patients with higher mortality. This is especially important for assessing the clinical status and would be of great value in patient triage/risk stratification. A patient with a higher CT intensity may benefit from initial ICU admission and aggressive treatment. It can expel the patient in the emergency department, especially in the context of shortages in technical/human resources in intensive care units.

Our study was subjected to some limitations. Firstly, we investigated two CT features (CT-ss and pleural effusion) among a variety of chest CT features in COVID-patients that may add value to CT role in prognostication. Secondly, although pleura effusion was of no statistical significance to predict mortality in our study, given its rare incidence in NCIP, larger-scale studies may show pleural effusion or other rare CT features to be of predictive value. Thirdly, we employed a semiquantitative visual system to calculate the CT-

ss, which could be replaced by a computer-assisted (AI estimation) approach in future studies to increase the repeatability and decrease the subjectivity of the assessment. We merely included ICU-admitted patients in our study, which will result in selection bias when someone is generalizing our findings; thus, these results are only applicable to ICU patients requiring to be validated in other patient groups, such as in outpatient settings. We considered the short-term in-hospital mortality as the outcome in this study; studies with more extended follow-up periods may reveal different and even opposite results. However, we must emphasize that chest CT as a diagnostic and prognostic tool is neither necessary nor sufficient, and to put our results into use, it can only be used in patients whose chest CT is taken and available on the first day of admission. Finally, our study was conducted on a retrospective design, and our results should be validated in prospective studies.

Conclusion

In conclusion, our study found semiquantitative CT severity score as an easy to calculate and meaningfully predictive of mortality in patients with COVID-19 pneumonia. We hope this can help medical staff to triage and risk-stratify COVID-19 to pick out patients who are in need of more aggressive treatment and more intense care and to follow the therapy response in them. However, larger-scale studies and investigations with longer follow-up periods are needed to further validate the predictive value of semiquantitative CT severity score and to incorporate it into other clinicolaboratory tests for better resources allocation in this era of human/technical resource shortage.

References

1. Commission WMH. Wuhan Municipal Health Commission's Briefing on the Pneumonia Epidemic Situation. 2020.
2. WHO. Coronavirus.
3. Worldometer. COVID-19 Coronavirus Pandemic.
4. Zhou S, Wang Y, Zhu T, Xia L. CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China. *American Journal of Roentgenology*. 2020; 214: 1287-1294.
5. Xiong Y, Sun D, Liu Y, Fan Y, Zhao L, Li X, et al. Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes. *Investigative radiology*. 2020.
6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet*. 2020; 395: 507-513.
7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020; 395: 497-506.
8. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *Jama*. 2020; 323: 1061-1069.
9. Rawat U, Cohen SL, Levsky JM, Haramati LB. ACR white paper-based comprehensive dose reduction initiative is associated with a reversal of the upward trend in radiation dose for chest CT. *Journal of the American College of Radiology*. 2015; 12: 1251-1256.
10. Azadbakht J, Khoramian D, Lajevardi ZS, Elikaii F, Aflatoonian AH, Farhood B, et al. A review on chest CT scanning parameters implemented in COVID-19 patients: bringing low-dose CT protocols into play. *Egyptian Journal of Radiology and Nuclear Medicine*. 2021; 52: 1-10.
11. Chang Y-C, Yu C-J, Chang S-C, Galvin JR, Liu H-M, Hsiao C-H, et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT. *Radiology*. 2005; 236: 1067-1075.
12. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. *Radiology*. 2020.
13. Yuan M, Yin W, Tao Z, Tan W, Hu Y. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. *PLoS one*. 2020; 15: e0230548.
14. Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. *Investigative radiology*. 2020.
15. Lyu P, Liu X, Zhang R, Shi L, Gao J. The performance of chest CT in evaluating the clinical severity of COVID-19 pneumonia: identifying critical cases based on CT characteristics. *Investigative radiology*. 2020; 55: 412-421.
16. Kazemi MA, Ghanaati H, Moradi B, Chavoshi M, Hashemi H, Hemmati S, et al. Prognostic factors of initial chest ct findings for ICU admission and mortality in patients with covid-19 pneumonia. *Iranian Journal of Radiology*. 2020; 17.
17. Abbasi B, Akhavan R, Khameneh AG, Zandi B, Farrokh D, Rad MP, et al. Evaluation of the relationship between inpatient COVID-19 mortality and chest CT severity score. *The American Journal of Emergency Medicine*. 2021; 45: 458-463.